Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GC33

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Anti-GPC3 Monoclonal Antibody GC33

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1…
Introduction: Codrituzumab/GC33/RO5137382 (GC33) is a humanized monoclonal antibody that targets glypican-3 (GPC3), an oncofetal… Expand
Is this relevant?
2014
2014
Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
GC33 is a humanized mAb against human glypican-3 (GPC3). In the first-in-human study carried out in the USA, GC33 was well… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).
4100 Background: GC33 is a recombinant humanized monoclonal antibody against Glypican-3 (GPC3) which is highly expressed in HCC… Expand
Is this relevant?
2014
2014
Biomarker analysis of a randomized, placebo-controlled, double-blind, multicenter phase II trial of intravenous RO5137382/GC33 at 1600 mg Q2W in previously treated patients with unresectable advanced…
e15090 Background: Glypican-3 (GPC3) is an oncofetal protein frequently expressed in HCC. GC33 is a humanized monoclonal antibody… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
Purpose: GC33 is a novel recombinant fully humanized monoclonal antibody that binds to human glypican-3 (GPC3). The antitumor… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 1
Is this relevant?
2013
2013
A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC).
235 Background: Glypican-3 (GPC3) belongs to a family of cell-surface heparan sulfate proteoglycans and is specifically expressed… Expand
Is this relevant?
2011
2011
A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC).
4085 Background: Glypican 3 (GPC3) belongs to a family of cell-surface heparan sulfate proteoglycans and is specifically… Expand
Is this relevant?
2010
2010
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
Glypican 3 (GPC3), a glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan, is expressed in a majority of… Expand
Is this relevant?
2009
2009
Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
Previously, we demonstrated the antitumor efficacy of the anti-glypican-3 (GPC3) antibody GC33 in several human liver cancer… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Human glypican 3 (GPC3) is preferentially expressed in the tumor tissues of liver cancer patients. In this study, we obtained a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE